Papabear

Papabear is an early-stage biotechnology company dedicated to developing novel therapeutics for pediatric cancers and rare diseases. The company focuses on addressing significant unmet medical needs in children, where traditional drug development has often lagged behind adult oncology. By leveraging specialized research into the unique molecular drivers of pediatric malignancies, Papabear aims to create targeted treatments that are both more effective and less toxic than current standards of care. The firm operates primarily in a pre-clinical capacity, advancing a pipeline of small molecule candidates designed to disrupt key pathways in rare childhood conditions.